The impact of '4 + 7' volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
| Autor: | Luxinyi Xu, Shicheng Yin, Siyu Hao, Zongfu Mao, Ying Yang, Lining Mao, Ruiwen Tong |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
National centralized drug procurement (NCDP) China medicine.medical_specialty medicine.drug_class media_common.quotation_subject Drug Costs Interrupted Time Series Analysis Health administration Volume-based procurement Procurement Environmental health medicine Humans Antihypertensive drug Antihypertensive drugs Antihypertensive Agents media_common business.industry Research Health Policy Public health Pharmaceutical Preparations Policy intervention Public aspects of medicine RA1-1270 Health Expenditures business |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 21, Iss 1, Pp 1-10 (2021) |
| ISSN: | 1472-6963 |
| DOI: | 10.1186/s12913-021-07143-3 |
| Popis: | Background In 2019, Chinese government launched a nationwide volume-based drug procurement aiming at reducing drug prices and saving drug costs through economies of scale, which aroused widespread attention. The first round of the policy pilot was implemented in 4 municipalities and 7 sub-provincial cities, referred to as “4 + 7” policy. In the “4 + 7” policy, 7 antihypertensive drugs were included. This study was conducted to evaluate the impact of “4 + 7” policy on the use of policy-related antihypertensive drugs. Method This study applied single-group Interrupted Time Series (ITS) design. We used drug purchasing data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. Antihypertensive drugs related to “4 + 7” policy were selected as study samples, including 7 drugs in the “4 + 7” List and 17 alternative drugs. Alternative drugs refer to antihypertensive drugs that have an alternative relationship with “4 + 7” List drugs in clinical use and have not yet been covered by the policy. “4 + 7” List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Purchase volume, expenditures, and daily costs were selected as outcome variables, and were measured using Defined Daily Doses (DDDs), Chinese Yuan (CNY), and Defined Daily Drug cost (DDDc). Results After “4 + 7” policy intervention, the procurement volume of bid-winning antihypertensive drugs significantly increased (3.12 million DDD, 95 % CI = 2.14 to 4.10, p CI= -2.83 to -1.82, p CI= -7.87 to -4.04, p CI= -1.43 to -1.18, p CI = 0.11 to 0.46, p CI = 0.03 to 0.25, p Conclusions The implementation of “4 + 7” policy promoted the drug use hypertensive patients gradually concentrated on the quality-guaranteed bid-winning drugs, which might be conducive to improve the overall quality level of drug use of Chinese hypertensive patients. Besides, a preliminary positive policy effect of price cut and cost-saving was observed in the antihypertensive drug category. In the future, price monitoring and drug use management regarding policy-related drugs should also be strengthened. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink